US HB19 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Republican 148-0)
Status: Introduced on December 9 2019 - 25% progression, died in committee
Action: 2019-12-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Pending: House Subcommittee on Antitrust, Commercial, and Administrative Law Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on December 9 2019 - 25% progression, died in committee
Action: 2019-12-19 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Pending: House Subcommittee on Antitrust, Commercial, and Administrative Law Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs. The bill generally limits payment amounts for drugs and biologics under Medicare medical services, reduces cost-sharing under the Medicare prescription drug benefit, modifies certain authorities and requirements under the Medicaid Drug Rebate Program, revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and establishes several reporting requirements for drug manufacturers with respect to drug prices.
Title
Lower Costs, More Cures Act of 2019
Sponsors
History
Date | Chamber | Action |
---|---|---|
2019-12-19 | House | Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. |
2019-12-10 | House | Referred to the Subcommittee on Health. |
2019-12-09 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-12-09 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-12-09 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-12-09 | House | Introduced in House |
Same As/Similar To
HB938 (Related) 2019-05-02 - Placed on the Union Calendar, Calendar No. 24.
HB965 (Related) 2019-05-16 - Supplemental report filed by the Committee on the Judiciary, H. Rept. 116-55, Part III.
HB1264 (Related) 2019-02-15 - Referred to the Subcommittee on Health.
HB1499 (Related) 2019-05-10 - Placed on the Union Calendar, Calendar No. 30.
HB1503 (Related) 2021-01-05 - Became Public Law No: 116-290.
HB1520 (Related) 2020-12-22 - Became Public Law No: 116-246. (TXT | PDF)
HB1781 (Related) 2019-10-29 - Received in the Senate and Read twice and referred to the Committee on Finance.
HB1922 (Related) 2020-12-18 - Placed on the Union Calendar, Calendar No. 559.
HB2087 (Related) 2019-05-21 - Subcommittee Hearings Held.
HB2115 (Related) 2019-10-29 - Received in the Senate and Read twice and referred to the Committee on Finance.
HB2296 (Related) 2019-09-24 - Placed on the Union Calendar, Calendar No. 170.
HB2376 (Related) 2019-05-21 - Subcommittee Hearings Held.
HB3029 (Related) 2019-06-04 - Subcommittee Hearings Held.
HB3408 (Related) 2019-06-24 - Referred to the Subcommittee on Health.
HB3415 (Related) 2019-06-24 - Referred to the Subcommittee on Health.
HB3443 (Related) 2019-07-24 - Sponsor introductory remarks on measure. (CR E971)
HB5281 (Related) 2019-12-04 - Referred to the Subcommittee on Health.
SB801 (Related) 2019-03-14 - Read twice and referred to the Committee on Finance.
SB1227 (Related) 2019-06-28 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 131.
SB1636 (Related) 2020-12-15 - Held at the desk.
SB1999 (Related) 2019-06-27 - Read twice and referred to the Committee on Finance.
SB2051 (Related) 2019-06-28 - Read twice and referred to the Committee on Finance.
SB2740 (Related) 2019-12-14 - Referred to the Subcommittee on Health.
SB3013 (Related) 2019-12-10 - Read twice and referred to the Committee on Finance.
HB5444 (Related) 2019-12-18 - Referred to the Subcommittee on Health.
HB5882 (Related) 2020-02-12 - Referred to the House Committee on Energy and Commerce.
HB6155 (Related) 2020-03-09 - Referred to the House Committee on Energy and Commerce.
HB4400 (Related) 2019-09-20 - Referred to the Subcommittee on Health.
HB2700 (Related) 2019-06-26 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
SB3942 (Related) 2020-06-11 - Read twice and referred to the Committee on Finance.
HB7877 (Related) 2020-07-30 - Referred to the Subcommittee on Health.
HB7898 (Related) 2021-01-05 - Became Public Law No: 116-321.
SB3129 (Related) 2019-12-19 - Read twice and referred to the Committee on Finance.
HB965 (Related) 2019-05-16 - Supplemental report filed by the Committee on the Judiciary, H. Rept. 116-55, Part III.
HB1264 (Related) 2019-02-15 - Referred to the Subcommittee on Health.
HB1499 (Related) 2019-05-10 - Placed on the Union Calendar, Calendar No. 30.
HB1503 (Related) 2021-01-05 - Became Public Law No: 116-290.
HB1520 (Related) 2020-12-22 - Became Public Law No: 116-246. (TXT | PDF)
HB1781 (Related) 2019-10-29 - Received in the Senate and Read twice and referred to the Committee on Finance.
HB1922 (Related) 2020-12-18 - Placed on the Union Calendar, Calendar No. 559.
HB2087 (Related) 2019-05-21 - Subcommittee Hearings Held.
HB2115 (Related) 2019-10-29 - Received in the Senate and Read twice and referred to the Committee on Finance.
HB2296 (Related) 2019-09-24 - Placed on the Union Calendar, Calendar No. 170.
HB2376 (Related) 2019-05-21 - Subcommittee Hearings Held.
HB3029 (Related) 2019-06-04 - Subcommittee Hearings Held.
HB3408 (Related) 2019-06-24 - Referred to the Subcommittee on Health.
HB3415 (Related) 2019-06-24 - Referred to the Subcommittee on Health.
HB3443 (Related) 2019-07-24 - Sponsor introductory remarks on measure. (CR E971)
HB5281 (Related) 2019-12-04 - Referred to the Subcommittee on Health.
SB801 (Related) 2019-03-14 - Read twice and referred to the Committee on Finance.
SB1227 (Related) 2019-06-28 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 131.
SB1636 (Related) 2020-12-15 - Held at the desk.
SB1999 (Related) 2019-06-27 - Read twice and referred to the Committee on Finance.
SB2051 (Related) 2019-06-28 - Read twice and referred to the Committee on Finance.
SB2740 (Related) 2019-12-14 - Referred to the Subcommittee on Health.
SB3013 (Related) 2019-12-10 - Read twice and referred to the Committee on Finance.
HB5444 (Related) 2019-12-18 - Referred to the Subcommittee on Health.
HB5882 (Related) 2020-02-12 - Referred to the House Committee on Energy and Commerce.
HB6155 (Related) 2020-03-09 - Referred to the House Committee on Energy and Commerce.
HB4400 (Related) 2019-09-20 - Referred to the Subcommittee on Health.
HB2700 (Related) 2019-06-26 - Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
SB3942 (Related) 2020-06-11 - Read twice and referred to the Committee on Finance.
HB7877 (Related) 2020-07-30 - Referred to the Subcommittee on Health.
HB7898 (Related) 2021-01-05 - Became Public Law No: 116-321.
SB3129 (Related) 2019-12-19 - Read twice and referred to the Committee on Finance.
Subjects
Administrative law and regulatory procedures
Administrative remedies
Advisory bodies
Appropriations
Biological and life sciences
Business records
Cancer
Chemistry
Child health
Civil actions and liability
Competition and antitrust
Congressional oversight
Consumer affairs
Corporate finance and management
Cosmetics and personal care
Department of Health and Human Services
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Drug therapy
Executive agency funding and structure
Federal Trade Commission (FTC)
Food and Drug Administration (FDA)
Fraud offenses and financial crimes
Genetics
Government information and archives
Government studies and investigations
Health
Health care costs and insurance
Health information and medical records
Health personnel
Health programs administration and funding
Health technology, devices, supplies
Home and outpatient care
Hospital care
Immunology and vaccination
Income tax deductions
Income tax exclusion
Inflation and prices
Intellectual property
Intergovernmental relations
Judicial review and appeals
Licensing and registrations
Manufacturing
Marketing and advertising
Medicaid
Medical education
Medical research
Medical tests and diagnostic methods
Medicare
Office of the U.S. Trade Representative
Prescription drugs
Product development and innovation
Public participation and lobbying
Research and development
Retail and wholesale trades
State and local government operations
Trade agreements and negotiations
User charges and fees
Women's health
Administrative remedies
Advisory bodies
Appropriations
Biological and life sciences
Business records
Cancer
Chemistry
Child health
Civil actions and liability
Competition and antitrust
Congressional oversight
Consumer affairs
Corporate finance and management
Cosmetics and personal care
Department of Health and Human Services
Digestive and metabolic diseases
Drug safety, medical device, and laboratory regulation
Drug therapy
Executive agency funding and structure
Federal Trade Commission (FTC)
Food and Drug Administration (FDA)
Fraud offenses and financial crimes
Genetics
Government information and archives
Government studies and investigations
Health
Health care costs and insurance
Health information and medical records
Health personnel
Health programs administration and funding
Health technology, devices, supplies
Home and outpatient care
Hospital care
Immunology and vaccination
Income tax deductions
Income tax exclusion
Inflation and prices
Intellectual property
Intergovernmental relations
Judicial review and appeals
Licensing and registrations
Manufacturing
Marketing and advertising
Medicaid
Medical education
Medical research
Medical tests and diagnostic methods
Medicare
Office of the U.S. Trade Representative
Prescription drugs
Product development and innovation
Public participation and lobbying
Research and development
Retail and wholesale trades
State and local government operations
Trade agreements and negotiations
User charges and fees
Women's health
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/19/all-info |
Text | https://www.congress.gov/116/bills/hr19/BILLS-116hr19ih.pdf |